PDSB
What one share of PDS Biotechnology holds
Pharmaceutical Preparations
In addition, we are developing the Infectimune® T cell-activator in infectious diseases.
PDS Biotechnology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.64 |
|---|---|
| Cash and investments | $0.10 |
| Book value | −$0.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | — | −$4.71 | $0.08 | −$4.85 | — | −$9.09 |
| 2014 | — | −$8.16 | $0.52 | −$6.28 | — | −$16.48 |
| 2016 | — | −$1.34 | $0.02 | −$1.14 | — | $3.09 |
| 2017 | — | −$1.67 | $0.01 | −$1.35 | — | −$0.02 |
| 2019 | — | −$1.44 | — | −$3.71 | — | $2.21 |
| 2020 | — | −$0.89 | — | −$0.79 | — | $1.22 |
| 2021 | — | −$0.66 | — | −$0.49 | — | $2.22 |
| 2022 | — | −$1.43 | — | −$0.90 | — | $1.46 |
| 2023 | — | −$1.39 | $0.00 | −$1.09 | — | $0.79 |
| 2024 | — | −$1.03 | $0.00 | −$0.96 | — | $0.50 |
| 2025 | — | −$0.74 | $0.00 | −$0.60 | — | $0.17 |